CADL Stock Summary and Trading Ideas (Candel Therapeutics | NASDAQ:CADL)

Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.

Candel Therapeutics trades on the NASDAQ stock market under the symbol CADL.

As of May 8, 2024, CADL stock price climbed to $10.83 with 1,118,567 million shares trading.

CADL has a beta of -0.58, meaning it tends to be less sensitive to market movements. CADL has a correlation of 0.00 to the broad based SPY ETF.

CADL has a market cap of $317.83 million. This is considered a Small Cap stock.

Last quarter Candel Therapeutics reported $0 in Revenue and -$.38 earnings per share. This fell short of revenue expectation by $-10,000 and missed earnings estimates by -$.22.

The top ETF exchange traded funds that CADL belongs to (by Net Assets): VTI, IWC, VXF, AVSC.

CADL has outperformed the market in the last year with a price return of +556.4% while the SPY ETF gained +27.0%. CADL has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +766.4% and +83.2%, respectively, while the SPY returned +4.2% and +2.3%, respectively.

CADL support price is $8.66 and resistance is $10.52 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CADL stock will trade within this expected range on the day.